Mechanistically, BLI targets JAK1 and inhibits its phosphorylation and JAK‐STAT activation, subsequently regulating the downstream signaling pathways to inhibit reactive oxygen species production, inflammation, and ferroptosis, thereby preventing the occurrence of kidney fibrosis and blocking the AKI–CKD transition process. The gene discussed is JAK1; the disease is chronic kidney disease.